COVID-19 in hematopoietic cell transplant recipients

被引：27

作者：

Altuntas, Fevzi ^{[1
,2
,3
]}

Ata, Naim ^{[4
]}

Yigenoglu, Tugce Nur ^{[1
,2
]}

Basci, Semih ^{[1
,2
]}

Dal, Mehmet Sinan ^{[1
,2
]}

Korkmaz, Serdal ^{[5
]}

Namdaroglu, Sinem ^{[6
]}

Basturk, Abdulkadir ^{[7
]}

Hacibekiroglu, Tuba ^{[8
]}

Dogu, Mehmet Hilmi ^{[9
]}

Berber, Ilhami ^{[10
]}

Dal, Kursat ^{[11
]}

Erkurt, Mehmet Ali ^{[10
]}

Turgut, Burhan ^{[12
]}

Ulgu, Mustafa Mahir ^{[13
]}

Celik, Osman ^{[14
]}

Akunal, Abdullah ^{[13
]}

Birinci, Suayip ^{[15
]}

机构：

[1] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey

[2] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Bone Marrow Transplantat Ctr, Ankara, Turkey

[3] Yildirim Beyazit Univ, Dept Internal Med, Div Hematol, Ankara, Turkey

[4] Minist Hlth, Dept Strategy Dev, Ankara, Turkey

[5] Univ Hlth Sci, Kayseri Training & Res Hosp, Dept Hematol, Kayseri, Turkey

[6] Univ Hlth Sci, Bozyaka Training & Res Hosp, Dept Hematol, Izmir, Turkey

[7] Selcuk Univ, Sch Med, Dept Internal Med, Div Hematol, Konya, Turkey

[8] Sakarya Univ, Sch Med, Dept Internal Med, Div Hematol, Sakarya, Turkey

[9] Istanbul Training & Res Hosp, Dept Hematol, Istanbul, Turkey

[10] Inonu Univ, Sch Med, Dept Internal Med, Div Hematol, Malatya, Turkey

[11] Kecioren Training & Res Hosp, Dept Internal Med, Ankara, Turkey

[12] Namik Kemal Univ, Sch Med, Dept Internal Med, Div Hematol, Tekirdag, Turkey

[13] Minist Hlth, Gen Directorate Hlth Informat Syst, Ankara, Turkey

[14] Minist Hlth, Publ Hosp Gen Directorate, Ankara, Turkey

[15] Hlth, Ankara, Turkey

来源：

BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / 04期

关键词：

D O I：

10.1038/s41409-020-01084-x

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.

引用

页码：952 / 955

页数：4

共 50 条

[1] COVID-19 in hematopoietic cell transplant recipients
Fevzi Altuntas
Naim Ata
Tugce Nur Yigenoglu
Semih Bascı
Mehmet Sinan Dal
Serdal Korkmaz
Sinem Namdaroglu
Abdulkadir Basturk
Tuba Hacıbekiroglu
Mehmet Hilmi Dogu
İlhami Berber
Kursat Dal
Mehmet Ali Erkurt
Burhan Turgut
Mustafa Mahir Ulgu
Osman Celik
Abdullah Akunal
Suayip Birinci
[J]. Bone Marrow Transplantation, 2021, 56 : 952 - 955
[2] COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study
Bhatt, Neel S.
Sharma, Akshay
Martin, Andrew St.
Martens, Michael
Riches, Marcie L.
Dandoy, Christopher E.
Auletta, Jeffery J.
[J]. BLOOD, 2021, 138
[3] Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients
Malek, Alexandre E.
Adachi, Javier A.
Mulanovich, Victor E.
Sassine, Joseph
Raad, Issam I.
McConn, Kelly
Seiler, Garret T.
Dhal, Udit
Khawaja, Fareed
Chemaly, Roy F.
[J]. TRANSPLANT INFECTIOUS DISEASE, 2021,
[4] Outcomes of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: Multicenter Retrospective Analysis
Narendra Agrawal
Reema Singh
Sanjeev Kumar Sharma
Rahul Naithani
Rahul Bhargava
Dharma Choudhary
Preethi Jeyaraman
Sachin Bansal
Divya Doval
Vipin Khandelwal
Nitin Bansal
Rayaz Ahmed
Dinesh Bhurani
[J]. Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 388 - 393
[5] Impact of COVID-19 in Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplant Recipients
Shao Jingxuan
Liu, Rongrong
Lai, Yongrong
Wei, Xinmei
Zhang, Ning
Huang, Cuifeng
Liu, Qifa
Zhang, Zhongming
Yang, Gaohui
Wei, Zhenbin
Liu, Lianjin
[J]. BLOOD, 2023, 142
[6] Quality of life and financial toxicity of hematopoietic stem cell transplant recipients in COVID-19
Oshiro, Natalia Naome
Nogueira, Luciana de Alcantara
dos Santos, Yasmin Hiorrana
Guimaraes, Paulo Ricardo Bittencourt
Kalinke, Luciana Puchalski
[J]. REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2023, 31
[7] Quality of life and financial toxicity of hematopoietic stem cell transplant recipients in COVID-19
Oshiro, Natalia Naome
Nogueira, Luciana de Alcantara
dos Santos, Yasmin Hiorrana
Guimaraes, Paulo Ricardo Bittencourt
Kalinke, Luciana Puchalski
[J]. REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2023, 31
[8] Outcomes of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: Multicenter Retrospective Analysis
Agrawal, Narendra
Singh, Reema
Sharma, Sanjeev Kumar
Naithani, Rahul
Bhargava, Rahul
Choudhary, Dharma
Jeyaraman, Preethi
Bansal, Sachin
Doval, Divya
Khandelwal, Vipin
Bansal, Nitin
Ahmed, Rayaz
Bhurani, Dinesh
[J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 388 - 393
[9] Quality of life and financial toxicity of hematopoietic stem cell transplant recipients in COVID-19
Oshiro, Natalia Naome
Nogueira, Luciana de Alcantara
dos Santos, Yasmin Hiorrana
Guimaraes, Paulo Ricardo Bittencourt
Kalinke, Luciana Puchalski
[J]. REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2023, 31
[10] COVID-19 and HSCT (Hematopoietic stem cell transplant)
Strasfeld, Lynne
[J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2022, 35 (03)

← 1 2 3 4 5 →